PCART30

N/A

Report date: 2025/02/19 10:32:23

Base Information

Drug NamePCART30
Drug Alias NamePCART30PCART-30
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProgrammed cell death protein 1 blockersNK cell lectin-like receptor subfamily C member 1 antagonists
TargetsProgrammed cell death protein 1NK cell lectin-like receptor subfamily C member 1
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedisix Therapeutics Pte Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMedisix Therapeutics Pte Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A